Vitrolife AB · OMXSTO:VITR
Vitrolife AB — Shareholder Meeting (2025)
19 slides from Vitrolife AB's shareholder meeting presentation, Apr 30, 2025
Slide 1: Anförande av verkställande direktören (in English)
7. Anförande av verkställande direktören (in English) 1
Slide 2: The IVF market
VITROLIFE GROUP™
Slide 3: The sheer magnitude of the global infertility healthcare issue
The sheer magnitude of the global infertility healthcare issue Adults >20 years old Adults >20 living Adults affected Coronary artery disease with Diabetes by infertility 3 Source: CDC International Diabetes Foundation, ESHRE, SART
Slide 4: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Organ
Slide 5: The Vitrolife Group corporate strategy
The Vitrolife Group corporate strategy 5
Slide 6: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Market Labour Growth in and skills Consoli- Regionali- Patient megatrends demand shortage dation sation Empowerment Our values Vision with a purpose Long-term growth and profit-targets (5 years) Integrity ”Enable people to fulfil the dream of having a healthy baby” A
Slide 7: Ensuring sustainability in everything we do
Ensuring sustainability in everything we do Our sustainability themes Purpose-driven Ethical Planet Inclusive growth profitability accountability engagement Maintain excellence in Alignment of all suppliers, Align the Group carbon Ensure a diverse, customer satisfaction, partners and distributors emi
Slide 8: The Vitrolife Group IVF platform
The Vitrolife Group IVF platform 8
Slide 9: IVF will become more automated and integrated – our platform approach
IVF will become more automated and integrated – our platform approach Egg retrieval Sperm processing Insemination and ICSI Embryo culture and evaluation Transfer/Cryopreservation Consumables tracking Equipment Quality Control Sample and procedure tracking Data 9
Slide 10: Vitrolife Group acquired eFertility
Vitrolife Group acquired eFertility • eFertility, an innovative system and software company transforming IVF clinic management. • eFertility offers both a witnessing system and EMR platform. • eWitness is an error prevention system that optimises lab workflow and enhance security with reliable insigh
Slide 11: Latest status on PGT-A lawsuit
Latest status on PGT-A lawsuit 11
Slide 12: Background on PGT-A: In a nutshell
Background on PGT-A: In a nutshell What is PGT-A test? Only if IVF Physician deems appropriate to the Clinical Case at hand, PGT-A testing may be prescribed. Therefore, it is critical to highlight: PGT-A is a genetic study of the embryo produced during IVF treatment to identify numerical chromosom
Slide 13: Financial result Full Year 2024 / First quarter 2025
Financial result Full Year / 2024 First quarter /2025 13
Slide 14: Full year 2024
Full year 2024 Sales Organic growth Gross margin 3,609 MSEK +4% 59.3% (3,512 MSEK) +3% in SEK In local currencies (56.3%) EBITDA Operating cash flow Earnings per share* 1,225 MSEK 907 MSEK 3.78 SEK Margin 34.0% (32.3%) (757 MSEK) (-28.44** SEK) Q1 2024 Q2 2024 Q3 2024 Q4 2024 Sales, MSEK 841 941 867
Slide 15: Sales and growth per geographical segment 2024
Sales and growth per geographical segment 2024 Americas EMEA APAC Total Organic growth* +1% +7% +5% +4% Sales (MSEK) 1,148 1,376 1,085 3,609 Share of total sales 32% 38% 30% 15 * Organic growth in local currencies
Slide 16: Q1/2025 Highlights
Q1 /2025 Highlights Q1 /2025 Highlights Growth EMEA Americas Strengthened +1%* +14%* +9%* +9%** organizational organisational structure * Organic growth in local currencies excluding discontinued business 16 **Organic growth in local currencies
Slide 17: Q1 2025: Strong performance in EMEA
Q1 2025: Strong performance in EMEA First quarter 2025 Sales Organic growth in local currencies Gross margin excluding discontinued business 842 MSEK +3% 57.4% (841 MSEK) 0% in SEK +1% in local currencies (57.1%) EBITDA Operating cash flow Earnings per share 257 MSEK 69 MSEK 0.74 SEK Margin 30.6% (32
Slide 18: Focus for 2025
Focus for 2025 1. Continue to drive share gain in key markets leveraging the full breadth of the portfolio. 2. Accelerate penetration of our combined EmbryoScope and lab control solutions. Growth 3. Deliver best in class quality and customer service to further differentiate from competitors. 1. Prio
Slide 19: Q&A – Reasons to invest in Vitrolife AB (publ)
Q&A Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Thank y